| The genetic architecture of multiple myeloma. | |
| | |
MedLine Citation:
|
PMID: 22495321 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Based on the clinical features of myeloma and related malignancies of plasma cells, it has been possible to generate a model system of myeloma progression from a normal plasma cell through smouldering myeloma to myeloma and then plasma cell leukaemia. Using this model system we can study at which points the genetic alterations identified through whole-tumour molecular analyses function in the initiation and progression of myeloma. Further genetic complexity, such as intraclonal heterogeneity, and insights into the molecular evolution and intraclonal dynamics in this model system are crucial to our understandings of tumour progression, treatment resistance and the use of currently available and future treatments. |
| | |
Authors:
|
Gareth J Morgan; Brian A Walker; Faith E Davies |
Publication Detail:
|
Type: Journal Article; Review Date: 2012-04-12 |
Journal Detail:
|
Title: Nature reviews. Cancer Volume: 12 ISSN: 1474-1768 ISO Abbreviation: Nat. Rev. Cancer Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: 2012-07-09 Revised Date: 2012-10-23 |
Medline Journal Info:
|
Nlm Unique ID: 101124168 Medline TA: Nat Rev Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 335-48 Citation Subset: IM |
Affiliation:
|
Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research and Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. gareth.morgan@icr.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clonal Evolution Disease Progression Genetic Heterogeneity* Humans Multiple Myeloma / genetics*, pathology, therapy Plasma Cells / cytology Tumor Markers, Biological / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Screening for cancer with molecular markers: progress comes with potential problems.
Next Document: Out of sight, out of mind: The presence of forensic evidence counts more than its absence.